OpenAI Launches GPT-Rosalind — Its First Life Sciences Model for Drug Discovery and Genomics (April 2026)

OpenAI on April 16, 2026 released GPT-Rosalind, its first frontier reasoning model purpose-built for life sciences research, and at the same time shipped a free Life Sciences plugin for Codex that connects developers to more than 50 scientific tools and databases. The model is named after British chemist Rosalind Franklin, whose X-ray diffraction work helped reveal the structure of DNA, and launches as a trusted-access research preview for qualified U.S. enterprise customers including Amgen, Moderna, the Allen Institute, and Thermo Fisher Scientific.

What Happened

OpenAI announced GPT-Rosalind on its own blog and in a coordinated press push with Axios, VentureBeat, MarkTechPost, and Euronews on April 16, 2026. The model is trained on 50 standard biological workflows and fine-tuned to interface with major public biology databases. According to OpenAI's own announcement, GPT-Rosalind is designed to propose likely reaction pathways, prioritize drug targets, and infer structural or functional properties of proteins, rather than simply recall facts from published literature.

Access is restricted — this is not a public product. OpenAI is routing the model through a "trusted access" program limited to qualified U.S. enterprise customers focused on health outcomes and legitimate research. Once inside, scientists can use GPT-Rosalind from ChatGPT, the OpenAI API, or Codex, the same surfaces that host GPT-5.4.

Key Details

• Frontier reasoning, biology-specialized — a domain-tuned sibling to GPT-5.4, not a general-purpose chatbot. The model is optimized for multi-step scientific workflows: evidence synthesis, hypothesis generation, experimental planning, and reagent design.
• BixBench pass rate of 0.751 — on this bioinformatics benchmark covering sequencing data processing, statistical analyses, and genomic interpretation, GPT-Rosalind posted a pass rate of 0.751, a meaningful jump over prior general models.
• Beats GPT-5.4 on 6 of 11 LABBench2 tasks — the sharpest gain is on CloningQA, which requires end-to-end design of reagents for molecular cloning protocols.
• 95th-percentile expert performance in an unpublished RNA study — in partnership with Dyno Therapeutics, the model's best submissions ranked above the 95th percentile of human experts on prediction tasks and hit the 84th percentile for sequence generation, using sequences the model had never seen.
• Codex Life Sciences plugin — shipping alongside GPT-Rosalind and freely available to Codex users, the plugin connects models to 50+ scientific tools and data sources, including public biological databases and computational pipelines.

What Developers and Users Are Saying

On Hacker News and r/MachineLearning, the early reaction is cautiously positive but focused on two questions. First: is this a genuinely better model, or is it GPT-5.4 with biology-flavored post-training and a marketing name? OpenAI's own benchmark chart shows wins on 6 of 11 LABBench2 tasks — a solid result but not a clean sweep, and researchers are already asking for independent reproductions on BixBench. Second: who gets in? The trusted-access program is by invitation and limited to U.S. enterprise customers, which has drawn complaints from academic labs and from overseas biotech teams hoping to benchmark the model themselves.

On the positive side, life sciences infrastructure accounts were bullish — the Codex Life Sciences plugin is freely available today and several biotech engineers on X/Twitter posted screenshots of it wiring up BLAST, Ensembl, and UniProt queries inside a single Codex session. Dyno Therapeutics co-signed the launch, which lends credibility to the RNA benchmark number.

What This Means for Developers and Researchers

For working drug-discovery and genomics teams at qualified U.S. enterprises, the practical change is that GPT-Rosalind is now available via ChatGPT, Codex, and the OpenAI API once access is granted via the life sciences access form. For everyone else — academics, overseas labs, indie bioinformaticians — GPT-Rosalind is behind a wall, but the Codex Life Sciences plugin is not. Any developer can wire Codex into 50+ scientific tools today without a special access tier, and the plugin is a useful automation layer on top of GPT-5.4.

For AI-industry watchers, the bigger signal is that OpenAI is following Google DeepMind (AlphaFold, Isomorphic Labs) into domain-specialized models rather than relying only on scaling a single general model. Expect similar specialized launches from Anthropic and the open-weight community — Arcee's recent Trinity-Large-Thinking showed the path for open-source agentic models, and biology is the obvious next frontier.

What's Next

OpenAI has not announced a public or consumer release date for GPT-Rosalind and has not committed to pricing outside the enterprise preview. Expect benchmark scrutiny over the next two to four weeks: independent teams on Hugging Face and in academic bioinformatics groups have already signaled they will try to reproduce LABBench2 and BixBench numbers on GPT-5.4 with targeted scaffolding, which will put pressure on OpenAI to publish a full model card. The Codex changelog is the best place to watch for plugin updates.

Sources

• OpenAI: Introducing GPT-Rosalind for life sciences research — the primary source announcement and benchmark chart.
• VentureBeat: OpenAI debuts GPT-Rosalind, a new limited access model for life sciences
• Axios: OpenAI launches new AI model for life sciences research
• MarkTechPost: OpenAI Launches GPT-Rosalind, a Specialized AI Model for Life Sciences
• Euronews: What to know about OpenAI's new model for life sciences research
• FierceBiotech: OpenAI launches biotech-specific AI model dubbed GPT-Rosalind